Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2023-10-24 Share Issue/Capital Cha…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated October 24, 2023, announcing the 'Closing of its Initial Public Offering on the Nasdaq Global Market'. It details the capital increase, the number of shares/ADSs offered, the offering price, and the gross proceeds, which are all characteristic of a financing or capital raising event. This directly aligns with the definition of 'Capital/Financing Update' (CAP). Although it relates to an IPO, the core subject is the successful completion of the capital raising activity.
2023-10-24 English
Abivax annonce la mise à disposition d’un prospectus dans le cadre de son offre au public d’actions ordinaires sous la forme d’ADS à l’occasion de son introduction en bourse sur le Nasdaq Global Marke
Capital/Financing Update Classification · 1% confidence The document is an announcement by Abivax regarding the approval of a prospectus ('prospectus') by the French financial regulator (AMF) for a public offering of ordinary shares in the form of ADSs related to its listing on the Nasdaq Global Market. The text explicitly mentions the components of the prospectus (universal registration document, amendments, offering note) and states that the prospectus can be consulted online. This structure—an announcement detailing the availability and approval of a formal offering document (prospectus)—strongly indicates a filing related to capital raising or a public offering. Among the provided codes, 'CAP' (Capital/Financing Update) is the most appropriate category for an announcement detailing a public offering and the associated prospectus approval, as it directly relates to fundraising activities. While it involves a regulatory document, it is specifically about a capital event, making CAP more precise than the general 'RPA' or 'RNS'.
2023-10-20 French
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Abivax announcing the resumption of trading of its ordinary shares on Euronext Paris following a suspension related to a global offering (including the listing of ADSs on Nasdaq). The text explicitly mentions the filing of a Universal Registration Document (Document d'Enregistrement Universel) with the AMF (French regulator) and discusses prospectus requirements and offering restrictions in the EEA and France. This type of announcement, detailing a significant corporate action involving capital markets (a global offering and subsequent trading resumption) and referencing regulatory filings/prospectuses, is best classified as a Capital/Financing Update (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV). While it mentions regulatory filings, the core subject is the financing/offering activity.
2023-10-20 French
Abivax announces trading resumption of its ordinary shares on Euronext Paris
Regulatory Filings Classification · 1% confidence The document is a short news release from Abivax, dated October 20, 2023, announcing the resumption of trading of its ordinary shares on Euronext Paris following a halt related to its ADS offering on Nasdaq. It contains minimal financial data and primarily serves as a corporate update regarding market activity. It is not a comprehensive annual report (10-K), interim report (IR), earnings release (ER), or a formal proxy/governance document. Since it is a general corporate announcement disseminated via a news service (EQS-News) that doesn't fit the specific categories like DIRS, DIV, or CAP, it falls best under the general Regulatory Filings/News category, which is RNS, or potentially a Report Publication Announcement (RPA) if it were announcing a report, but here it announces a trading event. Given the nature of the announcement (trading resumption related to an offering), RNS (Regulatory Filings/News) is the most appropriate general classification for this type of market-sensitive, non-periodic disclosure.
2023-10-20 English
Abivax annonce la fixation du prix de son introduction en bourse sur le Nasdaq Global Market
Capital/Financing Update Classification · 1% confidence The document is a press release dated October 20, 2023, announcing the pricing of Abivax's Initial Public Offering (IPO) on the Nasdaq Global Market through a capital increase. Key phrases include 'fixation du prix de son introduction en bourse sur le Nasdaq Global Market', 'augmentation de capital', and details about the offering price, underwriters, and intended use of proceeds. This clearly relates to fundraising and capital structure changes, fitting the definition of 'Capital/Financing Update'. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about a financing event.
2023-10-20 French
Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement titled "Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market." It details the offering price, the number of shares/ADSs being sold, the expected gross proceeds ($235.8 million), the use of proceeds, and mentions the involvement of underwriters and regulatory filings (like the Form F-1 registration statement and the French Universal Registration Document). This content is characteristic of a major financing event, specifically an Initial Public Offering (IPO) pricing announcement, which falls under the 'Capital/Financing Update' category.
2023-10-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.